Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programsTREMFYA® is the only IL-23 inhibitor to ...

Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products.

Johnson & Johnson announced that their Phase 3 GRAVITI study of Tremfya (guselkumab) SC therapy for Crohn's disease met...

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations.

Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...